Company Overview
Snapshot
Founded in January 2020 by Isaac Bentwich and Yossi Haran, Quris-AI operates with 51–200 employees. The company has raised $37 million across three funding rounds from 10 investors. A key milestone includes its expanded collaboration with Merck KGaA in September 2023, leveraging Quris-AI's platform to identify liver toxicity risks in drug candidates.
Business overview
Quris-AI is an artificial intelligence innovator focused on transforming the drug development process. The company's core offering is its Bio-AI Clinical Prediction Platform, which uses advanced machine learning to test drugs on miniaturized patients-on-a-chip. This technology generates and classifies data to continuously retrain algorithms, enabling accurate prediction of drug safety in humans and significantly reducing the costs associated with failed clinical trials. Quris-AI operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development industries.
Strategic signal
In September 2023, Quris-AI expanded its collaboration with pharmaceutical giant Merck KGaA, following a successful preclinical study. This extension allows Merck to further utilize Quris-AI's Bio-AI platform for identifying liver toxicity risks in drug candidates, with an option for a five-year exclusive license in a specific disease domain. This partnership signals strong commercial validation for Quris-AI's predictive technology and its potential to significantly de-risk early-stage drug development, attracting further interest from major pharmaceutical players.
Log in to access full profile ›Company Intelligence Q&A
- What was the most recent significant partnership for Quris-AI?
- In September 2023, Quris-AI extended its collaboration with Merck KGaA. This partnership focuses on leveraging Quris-AI's platform to identify liver toxicity risks in drug candidates, building on a successful preclinical study.
- What was Quris-AI's total capital raised?
- Quris-AI has raised a total of $37 million across three funding rounds.
- When was Quris-AI recognized by Fast Company?
- In March 2023, Quris-AI was named one of Fast Company's Most Innovative Companies for 2023, acknowledging its use of AI to disrupt drug development.
- What was a key strategic collaboration announced by Quris-AI in early 2023?
- In January 2023, Quris-AI announced a collaboration with Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) to establish a world-class Bio-AI center in Abu Dhabi, aiming to accelerate personalized medication development.
- Which investors participated in Quris-AI's seed funding round in December 2022?
- In December 2022, Quris-AI secured additional seed funding, with SoftBank Vision Fund 2.